Where to buy semaglutide.

You can buy semaglutide from a pharmacy on a prescription, as Ozempic, Wegovy or Rybelsus, or from a research-supply vendor as lab-grade powder. Those are the two legitimate answers to where to buy semaglutide in 2026. The compounding pharmacy route closed in mid-2025. The fourth channel, no-prescription sellers online, is where the documented counterfeits live.

Semaglutide

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

The Semaglutide referenced throughout this article, supplied as a research compound with a certificate of analysis matched to the lot you receive — the check this site argues you should hold any supplier to.

Shop Semaglutide

• CoA. Certificate of Analysis. A one-page lab report showing the specific lot's identity, purity, content, and contamination testing.
• ISO/IEC 17025. The international quality standard for testing labs. A 17025-accredited lab has been audited by a third party for technical competence.
• 503A / 503B. The two U.S. compounding tiers — 503A pharmacies fill individual prescriptions; 503B outsourcing facilities produce larger batches under FDA registration. Both compounded semaglutide legally only while the approved drug was in shortage.
• RUO. Research Use Only. A labeling category for laboratory materials that are not drugs, not for human or veterinary use, and carry no medical claims.
• LC-MS. Liquid chromatography–mass spectrometry. The identity test that confirms the molecule's mass — the single most direct check on what's actually in a vial.

What is semaglutide?

Semaglutide is a synthetic analog of GLP-1, the gut hormone that signals fullness and prompts glucose-dependent insulin release. Novo Nordisk made three changes to the native hormone.

An Aib substitution at position 8 blocks the DPP-4 enzyme from cutting it. An arginine goes in at position 34. And a C18 fatty di-acid chain hangs off the lysine at position 26 on a short spacer.

That fatty chain lets the peptide cling reversibly to albumin in your blood, which stretches its half-life to roughly 165 hours. About seven days. Lau and colleagues describe the design, and it's why the clinical programs could dose once a week.

The clinical record is why demand for this molecule dwarfs every other peptide. STEP-1 randomized 1,961 adults with overweight or obesity and reported a 14.9% mean body-weight reduction at 68 weeks on 2.4 mg, against 2.4% on placebo.

The SELECT cardiovascular trial followed 17,604 adults with established heart disease and reported a 20% relative cut in major cardiovascular events. That sits on top of the earlier SUSTAIN-6 signal in type 2 diabetes and the PIONEER program behind the oral pill.

All of that evidence belongs to the approved drug products. What matters to you as a research buyer is narrower. A genuine vial holds the same 31-residue acylated peptide, CAS 910463-68-2, formula C₁₈₇H₂₉₁N₄₅O₅₉, theoretical mass 4113.58 Da, as white lyophilized powder.

Everything else on a vendor's page is marketing until a third-party CoA confirms it.

Where can you buy semaglutide?

You can buy semaglutide from a pharmacy on a prescription, as Ozempic, Wegovy or Rybelsus, or from a research-supply vendor as lab powder. Those are the two legitimate routes. Semaglutide moves through four channels in 2026, and the other two aren't legitimate at all.

1. Prescription semaglutide (Ozempic, Wegovy, Rybelsus)

This is the only legal route for human use, and for most readers it's the real answer. Ozempic was approved for type 2 diabetes in 2017, Wegovy for chronic weight management in 2021, and Rybelsus as an oral tablet in 2019.

All three are FDA-approved finished drugs, made under cGMP and dispensed by a licensed pharmacy against your prescription. US cash list pricing for Wegovy has run near $1,350 per month, softened by insurance and manufacturer cash-pay programs.

If what you want is treatment, stop here. This channel is your answer and the rest of this article is about something else.

2. Compounded semaglutide: the channel that closed

This was the dominant sourcing story of 2023 to 2025. When the approved products hit the FDA drug shortage list in 2022, federal law temporarily let 503A pharmacies and 503B outsourcing facilities compound their own.

A telehealth-plus-compounding industry grew to millions of patients on that exception. The FDA then flagged a shortcut inside the boom. Some compounders were sourcing semaglutide sodium and semaglutide acetate salt forms, which the agency said in 2023 were different active ingredients from the base in the approved drugs.

Then the shortage ended. The FDA declared it resolved in February 2025 and set wind-down dates: April 22, 2025 for 503A pharmacies, May 22, 2025 for 503B facilities. Court challenges didn't stall either deadline.

What's left is a narrow case-by-case pathway that needs a documented clinical reason a specific patient can't use the approved product. As a route you can just sign up for, compounded semaglutide is gone. A vendor still selling "compounded semaglutide" subscriptions in 2026 is operating outside FDA guidance.

3. Research-supply vendors (the RUO channel)

This is the channel the rest of the guide is about, and we want to be plain about what it is. Research-supply vendors sell semaglutide as lyophilized bulk peptide labeled Research Use Only, for receptor assays, analytical method development, stability studies and reference-standard comparisons.

That's lab-reagent supply. It isn't a pharmacy, it isn't a workaround to the wind-down, and it isn't a substitute for a prescription. You get no prescriber, no sterile fill-finish for human administration, and no FDA review of the finished article.

Documentation is what separates the credible end of this channel from the rest. Ask for a batch-matched CoA from an ISO 17025-accredited third-party lab, with mass-spec identity, HPLC purity ≥98–99%, measured content and endotoxin testing. The semaglutide-specific checks come next.

Six vendors inside that channel, ordered the way our supplier comparison orders them — on what each one will show you rather than what it claims — with every column pulled from the vendor's own storefront on 13 August 2026; there is no verified semaglutide price anywhere in that set, so pricing is benchmarked on BPC-157 across the same vendors and no price column appears here.

† Behemoth Labz publishes real certificates, but the newest genuine document we could open was dated 2024-08-08 — roughly two years old. This table is the research-supply channel only; if what you want is treatment, channel 1 above is the answer and none of these rows applies to you. Stock varies by compound, so confirm a vendor lists semaglutide before you compare — what these columns describe is disclosure practice, and that is the part that travels across every compound a vendor sells. Disclosure: this site earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to. Every column above is a document you can open or a page you can load yourself.

Several vendors list semaglutide under a codename rather than the compound name, and a codename is not an identity check. The identity check is CAS 910463-68-2 on the certificate's identity line with an observed intact mass of 4113.58 Da and endotoxin reported at <1.0 EU/mg — require the CAS and the mass on the document before you accept that a codenamed listing is this molecule.

4. The counterfeit and no-questions-asked channel

The vacuum the wind-down left did not go unfilled. A 2024 market-surveillance study mapped the no-prescription online market, and the numbers are stark. Of 317 online-pharmacy links surfaced by search engines, 42.3% led to illegal operations.

The top 30 affiliated domains drew over 4.7 million visits in one quarter of 2023. When Ashraf and colleagues test-purchased from six of these sellers, three orders never arrived at all. All three vials that did arrive were judged probable substandard or falsified products.

The counterfeit problem reaches into legitimate-looking supply too. US and EU regulators seized counterfeit branded pens out of real distribution chains in 2023 and 2024. The WHO issued a global alert on falsified semaglutide in 2024, and some falsified European pens turned out to contain insulin.

A 2026 analysis of the EudraVigilance safety database found 234 case reports tied to suspected counterfeit semaglutide. Zinzi and colleagues classified 89.3% of the suspected reactions as serious, with hypoglycemia disproportionately reported against genuine product. That's the signature you'd expect from insulin-substituted fakes.

No other compound we cover has a documented counterfeit record like this one.

How do you verify semaglutide before you buy?

Four checks decide whether a semaglutide vial is what its label says. Mass-spec identity at 4113.6 Da. Measured content, not a restated label claim. A named salt form. And endotoxin testing. The standard eight criteria for any peptide vendor apply on top.

1. Mass-spec identity at ~4113.6 Da

Semaglutide's theoretical mass is 4113.58 g/mol, so the LC-MS line on the CoA should report an observed mass within about 1 Da of 4113.6. That one number rules out most substitutions. Tirzepatide sits near 4813 Da, liraglutide near 3751 Da, and filler or an unrelated peptide won't land close.

Our tirzepatide sourcing guide runs the same check from the other direction. Grey vendors have been caught shipping cheaper semaglutide under tirzepatide labels, and a 700 Da gap is impossible to miss on a competent instrument. A CoA with no mass-spec line rules out nothing.

2. Quantitation: the label number vs the vial number

This check matters more here than on any other compound we cover. The documented grey-market failure usually isn't the wrong molecule. It's the wrong amount.

In the 2024 test-purchase study, every delivered vial held real semaglutide. But measured content exceeded the label claim by 28.6–38.7%, and measured purity ran well below specification.

Content that misses the label in either direction wrecks any quantitative work. A reference compound whose real mass nobody knows isn't a reference compound. So the CoA has to state measured net peptide content per vial, not just repeat the label.

3. Salt form: base, sodium, and the acetate counter-ion

The word "semaglutide" on a label can hide three different chemistry stories. The approved drugs use semaglutide base. The shortage-era compounding market filled up with semaglutide sodium, a salt form the FDA flagged as a different active ingredient that didn't qualify for compounding.

Legitimately synthesized research peptide usually ships as an acetate salt. That's normal solid-phase synthesis chemistry, provided the CoA says so and quantifies it. Verified material caps the acetate counter-ion at 12% w/w.

Counter-ion plus residual water is exactly why the gross vial weight overstates net peptide, and why the quantitation above has to be measured rather than assumed. A vendor who can't tell you which form they sell hasn't characterized their own product.

4. Endotoxin and the pen rule

The same test-purchase study found endotoxin in every delivered grey-market sample, at 2.2–9.0 EU/mg against a standard specification of <1.0 EU/mg. Endotoxin ruins cell-based and in-vivo work no matter how pure the peptide is, so the LAL line on the CoA isn't optional.

Then one bright line. Research-supply semaglutide is lyophilized powder in a sealed vial. A pre-filled "semaglutide pen" sold outside a pharmacy is not research material. Pens are finished pharmaceutical articles, and the grey pen trade is where the worst counterfeits turned up, including the insulin-substituted ones.

What does semaglutide cost in 2026?

Research-grade semaglutide costs $60–$130 per 10 mg vial in 2026, against a US cash list price near $1,350 a month for Wegovy. Semaglutide is a long, modified peptide: 31 residues plus a fatty di-acid chain and spacer chemistry. It's also made at enormous scale in 2026, and the research market prices accordingly. Here's where retail should sit.

• 5 mg vial: $35–$70 ($7–$14/mg). Entry size, less common as demand consolidated on larger vials.
• 10 mg vial: $60–$130 ($6–$13/mg). The most common retail size across the market.
• 15 mg vial: $90–$180 ($6–$12/mg). Better per-mg value; the standard size for quantitative work.
• Multi-vial packs: 10–25% off on 3-packs and 6-packs at most reputable suppliers.

Put those numbers next to the pharmacy: roughly $1,350/month list for Wegovy against tens of dollars for a grey vial. That gap is the single force that built the illegitimate semaglutide market.

It's also why the cheapest listings attract the worst material. The 2024 test-purchase study deliberately bought from the lowest-price tier of no-prescription sellers, and every delivered vial failed. Our GLP-1 class comparison shows how pricing stacks across the incretin class.

Below roughly $40 per 10 mg, stop and ask why. Synthesis at scale is cheap, but HPLC purification, third-party ISO 17025 testing, endotoxin screening and quantitation are not. The bottom of the market skips those steps rather than engineering its way past them. Above about $18/mg, you're paying retail markup rather than chemistry.

Is semaglutide legal to buy?

Semaglutide's legal position is unusual for this library. Unlike most research peptides, it is an approved drug, and that cuts both ways for you.

• United States (FDA): Approved as Ozempic, Wegovy, and Rybelsus — prescription-only for human use. The raw peptide may be legally sold as a research reference compound labeled for laboratory use only, the same framework that covers other analytical reference standards (FDA RUO labeling). Selling research material for human consumption is illegal.
• Compounding: The shortage-era allowance ended in 2025. Routine compounded semaglutide is no longer a lawful channel.
• European Union (EMA): Approved as a prescription medicine; the falsified-medicines directive framework is what EU counterfeit seizures were run under.
• WADA: Not explicitly named on the Prohibited List; GLP-1 receptor agonists have drawn monitoring attention in athletic contexts (WADA Prohibited List for current categorizations).
• Customs: Import of finished drug products (pens) without a prescription is a seizure risk in most jurisdictions; research-labeled bulk peptide is treated as a laboratory chemical but remains subject to national rules.

As plainly as we can say it: research supply is lab-reagent supply. The wind-down of compounding did not turn research vendors into pharmacies, and a research vial is not a route to therapy.

A vendor marketing research-grade semaglutide as a cheaper Wegovy is misbranding a drug. Buy from them and you attach your work to their legal exposure.

What are the red flags when buying semaglutide?

Eight things would stop us buying a semaglutide vial. This compound has the worst documented counterfeit record in the peptide market, so we hold it to a harder standard than anything else we cover.

• Pre-filled pens sold as “research” product. Pens are finished pharmaceuticals. Outside a pharmacy they are, at best, diverted — and the documented counterfeit epicenter, including falsified pens that contained insulin.
• No quantitation on the CoA. Label-vs-content mismatch of 29–39% is the published gray-market norm, not a tail risk. A CoA that only restates the label claim has not measured the vial.
• No mass-spec line, or a mass far from 4113.6 Da. If the mass is wrong, the molecule is wrong — in either direction of the semaglutide/tirzepatide substitution trade.
• Salt-form silence. “Semaglutide sodium” sold as if it were the base compound, or a CoA with no named form and no counter-ion quantitation.
• “Compounded semaglutide, no prescription needed.” Post-wind-down, that sentence describes an illegal product twice over.
• Pricing far below the floor. Sub-$40 per 10 mg listings cluster exactly where the failed test purchases came from.
• Obesity-indication marketing on a research listing. Outcome claims, before/after imagery, or titration schedules copied from the drug label mean the vendor is selling an unapproved drug, not a reagent — FDA jurisdiction, not semantics.
• Missing endotoxin testing. Every audited gray-market sample exceeded the 1.0 EU/mg specification; a vendor who doesn't test can't know.

Semaglutide

15 mg ≥99% pure Lyophilized

31-aa GLP-1 analog with Aib-8 substitution and C18 di-acid acylation, CAS 910463-68-2. Batch-matched ISO 17025 third-party CoA with LC-MS identity, HPLC purity, endotoxin, and quantified acetate counter-ion on every lot. Research use only.

Learn more

Frequently asked questions

Is semaglutide legal to buy in the USA?

Two questions hide inside that one. As a medicine, yes, by prescription only: Ozempic, Wegovy or Rybelsus through a licensed pharmacy. As research material, also yes. Lyophilized peptide labeled for laboratory use is legal to buy and sell as a reference compound. Selling it for human consumption is illegal, and the research channel is not an alternative pharmacy.

Why did compounded semaglutide go away in 2025?

Because the legal basis for it was the shortage, and the shortage ended. The FDA declared it resolved in February 2025. 503A pharmacies had until April 22, 2025 and 503B facilities until May 22, 2025 to stop producing copies, and court challenges didn't stall either date. What's left is narrow and case-by-case, not the subscription model of 2023 and 2024.

What should a semaglutide CoA show?

Mass-spec identity near 4113.6 Da with CAS 910463-68-2 on the identity line. HPLC purity ≥98–99% with the chromatogram. Measured net peptide content per vial. Endotoxin under 1.0 EU/mg by LAL. A named, quantified counter-ion, usually acetate under about 12% w/w. The lab should be ISO/IEC 17025-accredited and named on the report. Our CoA reading guide walks each line.

Is research-grade semaglutide the same as Ozempic?

The same molecule when genuine, and a completely different product. Ozempic is a sterile cGMP drug in a metered pen with FDA oversight of every batch. Research-grade semaglutide is bulk lyophilized peptide whose quality rests entirely on the vendor's synthesis partner and third-party testing.

One is a medicine, the other a reagent. Treating the second as the first is the exact confusion this market's worst actors monetize.

What is semaglutide sodium, and should the vial say “base” or “acetate”?

Semaglutide sodium is the salt form the FDA flagged in 2023 when compounders were caught sourcing it. It's a different active ingredient from the base used in the approved drugs.

Research peptide legitimately ships as an acetate salt. That's standard synthesis chemistry, not a warning sign, so long as the CoA names the form and quantifies the counter-ion. The red flag is silence.

How does semaglutide compare to tirzepatide for research sourcing?

Semaglutide is the single-receptor GLP-1 benchmark. Tirzepatide adds GIP agonism and beat semaglutide 1 mg on every endpoint in the SURPASS-2 head-to-head, while semaglutide holds the SELECT cardiovascular win.

On sourcing, semaglutide is the cheaper synthesis, which is why it shows up as the substituted compound inside mislabeled tirzepatide vials. Our tirzepatide vs semaglutide piece has the full breakdown.

How common are semaglutide counterfeits, really?

Common enough to be documented at every level of the supply chain. Regulators seized counterfeit pens out of legitimate US and EU distribution. The WHO issued a global alert in 2024. The EU pharmacovigilance database holds 234 suspected-counterfeit case reports, 89.3% of them serious.

And a peer-reviewed test-purchase study saw 100% of delivered grey-market vials fail. No other peptide has a counterfeit literature like this, which is why we weight identity and quantitation testing more heavily here than anywhere else.